Literature DB >> 1561058

[Preliminary specification of X-ray CT for lung cancer screening (LSCT) and its evaluation on risk-cost-effectiveness].

T Iinuma1, Y Tateno, T Matsumoto, S Yamamoto, M Matsumoto.   

Abstract

In Japan mass screening for lung cancer is widely performed by chest X-ray film of 10 x 10 cm, with sputum cytology for high-risk groups. However, the effectiveness of the present mass screening program for lung cancer has been less than expected, although some date have shown improvement of the survival rate as a result of mass screening. We propose a new X-ray CT method of screening for lung cancer called Lung Cancer Screening CT (LSCT). The preliminary specifications for LSCT are as follows: scan speed is within 10 sec for a 40 cm length with a 1 cm slice thickness, and the absorption dose for lung is less than 1 cGy. A computer-assisted diagnostic system is necessary for image reading. The risk-benefit analysis of LSCT indicates that Japanese men and women over 45 years old can be screened in 1992 and thereafter. The cost per person.year of LSCT screening is estimated to be 1.4 x 10(6) yen for a population incidence rate of 50 x 10(-5) person/year and average life expectancy of 30 years. In 1992 the above condition will be satisfied by men aged 55 years old and above, but not by women of any age. We believe that LSCT should be developed further and tested in the high-risk group of men with an incidence rate of 100 x 10(-5) persons/year or more.

Entities:  

Mesh:

Year:  1992        PMID: 1561058

Source DB:  PubMed          Journal:  Nihon Igaku Hoshasen Gakkai Zasshi        ISSN: 0048-0428


  2 in total

Review 1.  Efficacy of low-dose computed tomography screening for lung cancer: the current state of evidence of mortality reduction.

Authors:  Motoyasu Sagawa; Takafumi Sugawara; Naoya Ishibashi; Akira Koyanagi; Takashi Kondo; Toshiharu Tabata
Journal:  Surg Today       Date:  2016-11-04       Impact factor: 2.549

2.  Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials.

Authors:  Muralikrishna Gopal; Shaad E Abdullah; James J Grady; James S Goodwin
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.